↓ Skip to main content

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

Overview of attention for article published in Annals of the Rheumatic Diseases, July 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Citations

dimensions_citation
246 Dimensions

Readers on

mendeley
125 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Published in
Annals of the Rheumatic Diseases, July 2012
DOI 10.1136/annrheumdis-2012-201766
Pubmed ID
Authors

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, Philip J Mease, Walter P Maksymowych, Matthew A Brown, Vipin Arora, Aileen L Pangan

Abstract

To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Australia 1 <1%
United Kingdom 1 <1%
Brazil 1 <1%
Netherlands 1 <1%
Canada 1 <1%
Singapore 1 <1%
Unknown 118 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 18%
Student > Ph. D. Student 22 18%
Other 15 12%
Student > Master 14 11%
Unspecified 12 10%
Other 39 31%
Readers by discipline Count As %
Medicine and Dentistry 78 62%
Unspecified 16 13%
Agricultural and Biological Sciences 11 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Social Sciences 3 2%
Other 12 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2018.
All research outputs
#619,900
of 12,361,872 outputs
Outputs from Annals of the Rheumatic Diseases
#352
of 4,818 outputs
Outputs of similar age
#5,624
of 121,229 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#4
of 107 outputs
Altmetric has tracked 12,361,872 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,818 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,229 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.